Who is sponsoring NCT00861328?

NCT00861328 is sponsored by Traws Pharma, Inc..

What condition does NCT00861328 study?

NCT00861328 studies Advanced Solid Tumors.

What drugs are being tested in NCT00861328?

Interventions: ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin.

What is the status of NCT00861328?

NCT00861328 is currently COMPLETED.

Last reviewed 2017-06-22 · How we verify

A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors

NCT00861328 Phase 1 COMPLETED

Treatment of cancer is often improved if two or more drugs are used in combination. In animal studies, the use of the combination of ON 01910.Na (a new, unapproved drug) and irinotecan or oxaliplatin (two approved and extensively used anti-cancer drugs) gave better results against tumor cells than the use of any of the single drugs alone. In addition, the use of the combinations did not result in an increase of side effects. This clinical trial will determine what is the highest dose of ON 01910.Na that can be given safely in combination with either irinotecan or oxaliplatin in human patients.

Details

Lead sponsor	Traws Pharma, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	18
Start date	2008-02
Completion	2011-07

Conditions

Advanced Solid Tumors

Interventions

ON 01910.Na and irinotecan
ON 01910.Na and oxaliplatin

Primary outcomes

maximum tolerated dose — 1 - 3 months

Countries

United States